The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $22.12. Discover ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. Pfizer ...

Pfizer PFE has announced that it is discontinuing development of its oral small molecule GLP-1 agonist, danuglipron, after one patient in a clinical trial experienced a liver injury that could ...

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...

Pfizer is ending the development of a one-daily weight-loss pill after a patient in a trial experienced a liver injury that was potentially caused by the drug. The patient's liver enzymes ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $125.5 billion, the company ...